Expression of PROX1 Is a Common Feature of High-Grade Malignant Astrocytic Gliomas
Expression of PROX1 Is a Common Feature of High-Grade Malignant Astrocytic Gliomas
复制标题
DOI：
10.1097/nen.0b013e3181ca4767
复制
发表时间：
2010-02-01
影响因子：
3.2
通讯作者：
Nister, Momca
中科院分区：
文献类型：
--
作者：
Elsir, Tarnador;Eriksson, Anna;Nister, Momca
PROX1是一种与prospero相关的转录因子，在包括哺乳动物淋巴系统和中枢神经系统在内的各种器官的发育中发挥着关键作用；它通过不同的转录途径控制细胞增殖和分化，并具有致癌和抑癌功能。我们使用免疫组织化学研究了 56 例不同级别的人星形细胞胶质瘤中的 PROM 表达模式。世界卫生组织 IV 级（胶质母细胞瘤，n = 15）中平均 79% 的细胞和世界卫生组织 III 级（间变性星形细胞瘤，n = 13）中平均 57% 的细胞呈 PROX1 强阳性；低级别弥漫性星形细胞瘤（11 级，n = 13）有 21% 的细胞呈强阳性； I级肿瘤（n = 15）为1.5%；非肿瘤性脑组织 (n = 15) 有 3.7% 的细胞呈 PROX1 阳性。双重免疫标记显示胶质母细胞瘤中的 PROX1+ 细胞经常共表达早期神经元蛋白 MAP2 和 β III-微管蛋白，但不表达成熟神经元标记蛋白 NeuN。与增殖标记物共表达的分析表明，PROX1+ 细胞的增殖率略低于其他特纳细胞，但仍具有有丝分裂活性。我们的结论是，PROX1 可能构成星形细胞胶质瘤的诊断和分级以及区分 III 级和 IV 级肿瘤与 I 级和 II 级肿瘤的有用工具。
PROX1 is a prospero-related transcription factor that plays a critical role in the development of various organs including the mammalian lymphatic and central nervous systems; it controls cell proliferation and differentiation through different transcription pathways and has both oncogenic and tumor-suppressive functions. We investigated PROM expression patterns in 56 human astrocytic gliomas of different grades using immunohistochemistry. An average of 79% of cells in World Health Organization Grade IV (glioblastoma, n = 15) and 57% of cells in World Health Organization Grade III (anaplastic astrocytoma, n = 13) were strongly PROX1 positive; low-grade diffuse astrocytomas (Grade 11, n = 13) had 21% of cells that were strongly positive; Grade I tumors (n = 15) had 1.5%; and non-neoplastic brain tissue (n = 15) had 3.7% of cells that were PROX1 positive. Double immunolabeling showed that PROX1+ cells in glioblastomas frequently coexpressed early neuronal proteins MAP2 and beta III-tubulin but not the mature neuronal marker protein NeuN. Analyses of coexpression with proliferation markers suggest that PROX1+ cells have a marginally lower rate of proliferation than other turner cells but are still mitotically active. We conclude that PROX1 may constitute a useful tool for the diagnosis and grading of astrocytic gliomas and for distinguishing Grade III and Grade IV tumors from Grade I and Grade II tumors.